Currently no disease-modifying or neuroprotective treatments exist for MSA, nor are there effective medications to treat the cerebellar ataxia in MSA-C or the parkinsonian features in MSA-P. Physical ...

– Company is advancing ATH434 in late-stage clinical development for Multiple System Atrophy, a rapidly progressive neurodegenerative disease with no approved therapies – MSA is a progressive ...

MELBOURNE, Australia and SAN FRANCISCO, Feb. 26, 2021 /PRNewswire/ -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), will present at the upcoming 7th ...

In a study published in Neuron, researchers have identified four new genetic risk factors for multiple system atrophy (MSA), shedding light on this poorly understood disorder. The study, which ...

Scientists have found a way to distinguish between two progressive neurodegenerative diseases, Parkinson's disease (PD) and multiple system atrophy (MSA). Scientists have found a way to distinguish ...

Multiple system atrophy (MSA) is a neurodegenerative disease with multiple debilitating symptoms. One of them is sleep disorders; however, owing to limited research, little is known about why only ...

Successful End-of-Phase 2 meeting with FDA agreeing on key elements of the proposed Phase 3 design, including study population, dosing regimen, ...

Emrusolmin is expected to improve symptoms of MSA by targeting alpha synuclein oligomers. The Food and Drug Administration (FDA) has granted Fast Track designation to emrusolmin (TEV-56286) for the ...

Multiple system atrophy (MSA) is a rare and fatal brain disorder with no available treatment or cure, attacking the nervous system, balance, and the ability to move. The disease in many ways resembles ...

Detailed price information for Alterity Therapeutics Ltd ADR (ATHE-Q) from The Globe and Mail including charting and trades.